Document Detail


Restoration of innate and adaptive immune responses by HCV viral inhibition with an induction approach using natural interferon-beta in chronic hepatitis C.
MedLine Citation:
PMID:  22966239     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Chronic hepatitis C (CHC) is a serious medical problem necessitating more effective treatment. This study investigated the hypothesis that an induction approach with nIFN-beta for 24 weeks followed by PEG-IFN-alpha+ribavirin (standard of care: SOC) for 48 weeks (novel combination treatment: NCT) would increase the initial virologic response rate and restore innate and adaptive immune responses in CHC. Seven CHC patients with a high viral load and genotype 1b were treated with NCT. Serum cytokine and chemokine levels were evaluated during NCT. NCT prevented viral escape and breakthrough resulting in persistent viral clearance of HCVRNA. IL-15 was increased at the end of induction therapy in both early virologic responders (EAVRs) and late virologic responders (LAVRs); CXCL-8, CXCL-10, and CCL-4 levels were significantly decreased (P < 0.05) in EAVR but not in LAVR during NCT, and IL-12 increased significantly (P < 0.05) and CXCL-8 decreased significantly (P < 0.05) after the end of NCT in EAVR but not in LAVR. NCT prevented viral breakthrough with viral clearance leading to improvement of innate and adaptive immunity resulting in a sustained virologic response (SVR). NCT (n = 8) achieved a higher SVR rate than SOC (n = 8) in difficult-to-treat CHC patients with genotype 1 and high viral loads.
Authors:
Y Kishida; N Imaizumi; H Tanimura; Y Haruna; S Kashiwamura; T Kashiwagi
Related Documents :
24756229 - Immune response is required for the control of in vivo translocation and chronic toxici...
24053409 - All-trans-retinoic acid improves immunocompetence in a murine model of lipopolysacchari...
24056119 - Retinoid signaling in pathological remodeling related to cardiovascular disease.
24652679 - Changes in matrix metalloprotease activity and progranulin levels may contribute to the...
12114629 - Mediation of poly(adp-ribose) polymerase-1-dependent cell death by apoptosis-inducing f...
23580489 - Lack of lymphatics and lymph node-mediated immunity in choroidal neovascularization.
11390439 - Immunoproteasomes shape immunodominance hierarchies of antiviral cd8(+) t cells at the ...
17675239 - Role of hla-g in innate immunity through direct activation of nf-kappab in natural kill...
11401999 - Brain granulomas in neurocysticercosis patients are associated with a th1 and th2 profile.
Publication Detail:
Type:  Journal Article     Date:  2012-08-27
Journal Detail:
Title:  Clinical & developmental immunology     Volume:  2012     ISSN:  1740-2530     ISO Abbreviation:  Clin. Dev. Immunol.     Publication Date:  2012  
Date Detail:
Created Date:  2012-09-11     Completed Date:  2013-01-31     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  101183692     Medline TA:  Clin Dev Immunol     Country:  Egypt    
Other Details:
Languages:  eng     Pagination:  582716     Citation Subset:  IM    
Affiliation:
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Osaka Kaisei Hospital 1-6-10 Miyahara, Yodogawa-Ku, Osaka City, Osaka 532-0003, Japan. y-kishida@muse.ocn.ne.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adaptive Immunity / drug effects*
Adult
Aged
Antiviral Agents / therapeutic use*
Chemokines / blood
Cytokines / blood
Drug Therapy, Combination
Female
Hepacivirus / drug effects*,  immunology
Hepatitis C, Chronic / drug therapy*,  immunology*,  virology
Humans
Immunity, Innate / drug effects*
Interferon-alpha / therapeutic use
Interferon-beta / therapeutic use*
Male
Middle Aged
Polyethylene Glycols / therapeutic use
RNA, Viral / blood
Recombinant Proteins / therapeutic use
Ribavirin / therapeutic use
Treatment Outcome
Viral Load / drug effects
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Chemokines; 0/Cytokines; 0/Interferon-alpha; 0/Polyethylene Glycols; 0/RNA, Viral; 0/Recombinant Proteins; 0/peginterferon alfa-2a; 36791-04-5/Ribavirin; 77238-31-4/Interferon-beta
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Periostin as a biomarker of the amniotic membrane.
Next Document:  Gene expression profile reveals abnormalities of multiple signaling pathways in mesenchymal stem cel...